A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Conjugated C-6 hydroxylated bile acids in serum relate to human metabolic health and gut Clostridia species

Julkaisun tekijät: Petersen Anders Ø, Julienne Hanna, Hyötyläinen Tuulia, Sen Partho, Fan Yong, Krogh Pedersen Helle, Jäntti Sirkku, Hansen Tue H., Nielsen Trine, Jørgensen Torben, Hansen Torben, Myers Pernille Neve, Nielsen H. Bjørn, Ehrlich S. Dusko, Orešič Matej, Pedersen Oluf

Kustantaja: Nature Research

Julkaisuvuosi: 2021

Journal: Scientific Reports

Lehden akronyymi: Sci Reports

Volyymi: 11

eISSN: 2045-2322

DOI: http://dx.doi.org/10.1038/s41598-021-91482-y


Knowledge about in vivo effects of human circulating C-6 hydroxylated bile acids (BAs), also called muricholic acids, is sparse. It is unsettled if the gut microbiome might contribute to their biosynthesis. Here, we measured a range of serum BAs and related them to markers of human metabolic health and the gut microbiome. We examined 283 non-obese and obese Danish adults from the MetaHit study. Fasting concentrations of serum BAs were quantified using ultra-performance liquid chromatography-tandem mass-spectrometry. The gut microbiome was characterized with shotgun metagenomic sequencing and genome-scale metabolic modeling. We find that tauro- and glycohyocholic acid correlated inversely with body mass index (P = 4.1e-03, P = 1.9e-05, respectively), waist circumference (P = 0.017, P = 1.1e-04, respectively), body fat percentage (P = 2.5e-03, P = 2.3e-06, respectively), insulin resistance (P = 0.051, P = 4.6e-4, respectively), fasting concentrations of triglycerides (P = 0.06, P = 9.2e-4, respectively) and leptin (P = 0.067, P = 9.2e-4). Tauro- and glycohyocholic acids, and tauro-a-muricholic acid were directly linked with a distinct gut microbial community primarily composed of Clostridia species (P = 0.037, P = 0.013, P = 0.027, respectively). We conclude that serum conjugated C-6-hydroxylated BAs associate with measures of human metabolic health and gut communities of Clostridia species. The findings merit preclinical interventions and human feasibility studies to explore the therapeutic potential of these BAs in obesity and type 2 diabetes.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Last updated on 2021-04-08 at 14:10